Header Logo

Connection

Mhairi Maskew to Prospective Studies

This is a "connection" page, showing publications Mhairi Maskew has written about Prospective Studies.
Connection Strength

0,800
  1. Preferences for services in a patient's first six months on antiretroviral therapy for HIV in South Africa and Zambia (PREFER): research protocol for a prospective observational cohort study. Gates Open Res. 2023; 7:119.
    View in: PubMed
    Score: 0,175
  2. Kaposi sarcoma-associated herpes virus and response to antiretroviral therapy: a prospective study of HIV-infected adults. J Acquir Immune Defic Syndr. 2013 Aug 01; 63(4):442-8.
    View in: PubMed
    Score: 0,085
  3. Tenofovir use and pregnancy among women initiating HAART. AIDS. 2012 Nov 28; 26(18):2393-7.
    View in: PubMed
    Score: 0,081
  4. Antiretroviral therapy initiation during tuberculosis treatment and HIV-RNA and CD4 T-lymphocyte responses. Int J Tuberc Lung Dis. 2012 Oct; 16(10):1358-64.
    View in: PubMed
    Score: 0,079
  5. Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South Africa. J Int AIDS Soc. 2012 Mar 12; 15(1):13.
    View in: PubMed
    Score: 0,077
  6. Attrition in HIV care following HIV diagnosis: a comparison of the pre-UTT and UTT eras in South Africa. J Int AIDS Soc. 2021 02; 24(2):e25652.
    View in: PubMed
    Score: 0,036
  7. Delays in repeat HIV viral load testing for those with elevated viral loads: a national perspective from South Africa. J Int AIDS Soc. 2020 07; 23(7):e25542.
    View in: PubMed
    Score: 0,034
  8. Impact of the test and treat policy on delays in antiretroviral therapy initiation among adult HIV positive patients from six clinics in Johannesburg, South Africa: results from a prospective cohort study. BMJ Open. 2020 03 25; 10(3):e030228.
    View in: PubMed
    Score: 0,034
  9. Prevalence, incidence, predictors, treatment, and control of hypertension among HIV-positive adults on antiretroviral treatment in public sector treatment programs in South Africa. PLoS One. 2018; 13(10):e0204020.
    View in: PubMed
    Score: 0,030
  10. Incident tuberculosis in HIV-positive children, adolescents and adults on antiretroviral therapy in South Africa. Int J Tuberc Lung Dis. 2016 08; 20(8):1040-5.
    View in: PubMed
    Score: 0,026
  11. Clinical Predictors of Culture-confirmed Pulmonary Tuberculosis in Children in a High Tuberculosis and HIV Prevalence Area. Pediatr Infect Dis J. 2015 Sep; 34(9):e206-10.
    View in: PubMed
    Score: 0,024
  12. Incidence rate of Kaposi sarcoma in HIV-infected patients on antiretroviral therapy in Southern Africa: a prospective multicohort study. J Acquir Immune Defic Syndr. 2014 Dec 15; 67(5):547-54.
    View in: PubMed
    Score: 0,023
  13. Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir. Trop Med Int Health. 2014 May; 19(5):490-8.
    View in: PubMed
    Score: 0,022
  14. The interplay between CD4 cell count, viral load suppression and duration of antiretroviral therapy on mortality in a resource-limited setting. Trop Med Int Health. 2013 May; 18(5):619-31.
    View in: PubMed
    Score: 0,021
  15. The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial. HIV Med. 2013 Apr; 14(4):217-25.
    View in: PubMed
    Score: 0,020
  16. A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect Dis. 2011 Sep 17; 11:244.
    View in: PubMed
    Score: 0,019
  17. The prevalence of hepatitis B co-infection in a South African urban government HIV clinic. S Afr Med J. 2008 Jul; 98(7):541-4.
    View in: PubMed
    Score: 0,015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.